Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

OptimizeRx (OPRX) Total Current Liabilities (2016 - 2025)

Historic Total Current Liabilities for OptimizeRx (OPRX) over the last 17 years, with Q3 2025 value amounting to $18.5 million.

  • OptimizeRx's Total Current Liabilities rose 2733.42% to $18.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $18.5 million, marking a year-over-year increase of 2733.42%. This contributed to the annual value of $18.7 million for FY2024, which is 431.72% up from last year.
  • As of Q3 2025, OptimizeRx's Total Current Liabilities stood at $18.5 million, which was up 2733.42% from $21.1 million recorded in Q2 2025.
  • Over the past 5 years, OptimizeRx's Total Current Liabilities peaked at $21.1 million during Q2 2025, and registered a low of $5.4 million during Q1 2021.
  • Moreover, its 5-year median value for Total Current Liabilities was $8.4 million (2022), whereas its average is $11.5 million.
  • In the last 5 years, OptimizeRx's Total Current Liabilities crashed by 4521.63% in 2021 and then surged by 17144.78% in 2024.
  • OptimizeRx's Total Current Liabilities (Quarter) stood at $9.4 million in 2021, then decreased by 10.38% to $8.4 million in 2022, then soared by 112.99% to $17.9 million in 2023, then increased by 4.32% to $18.7 million in 2024, then fell by 1.01% to $18.5 million in 2025.
  • Its Total Current Liabilities was $18.5 million in Q3 2025, compared to $21.1 million in Q2 2025 and $18.4 million in Q1 2025.